Evaluation of bioactivity and pharmacokinetic characteristics of PEGylated P.pastoris-expressed erythropoietin

Drug Delivery

Volumn 18, Issue 8, 2011, Pages 570-577

  Maleki, Ahmad ^a,b   Najafabadi, Abdolhossein Rouholamini ^a   Roohvand, Farzin ^b   Shafiee, Abbas ^a   Khanahmad, Hossein ^b   Faghihi, Homa ^a   Hedayati, Mohammad H ^b   Tajerzadeh, Hosnieh ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

Erythropoietic agent; In vitro In vivo activities; Mean Residence Time; Methylotrophic yeast; N terminal PEGylation

Indexed keywords

ALDEHYDE; COMPLEMENTARY DNA; MACROGOL; RECOMBINANT ERYTHROPOIETIN;

ALKYLATION; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CELL ASSAY; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG ISOLATION; EXPERIMENTAL RABBIT; EXPRESSION VECTOR; GENE AMPLIFICATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MEAN RESIDENCE TIME; MOLECULAR CLONING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PICHIA PASTORIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; REDUCTION; SINGLE DRUG DOSE;

ANIMALS; AREA UNDER CURVE; CELL LINE; CELL PROLIFERATION; CHROMATOGRAPHY, GEL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ERYTHROPOIESIS; ERYTHROPOIETIN; HUMANS; MALE; MEGAKARYOCYTES; MICE; MICE, INBRED STRAINS; PICHIA; POLYETHYLENE GLYCOLS; RABBITS; RECOMBINANT PROTEINS; RETICULOCYTE COUNT;

EID: 82055208332     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2011.600782     Document Type: Article

References (39)

1. Agoram B, Aoki K, Doshi S, Gegg C, Jang G, Molineux G, Narhi L, Elliott S. (2008). Investigation of the effects of altered receptor binding activity on the clearance of erythropoiesis-stimulating proteins: nonerythropoietin receptor-mediated pathways may play a major role. J Pharm Sci, 98, 2198-2211.
2. Bailon P, Berthold W. (1998). Polyethylene glycol-conjugated pharmaceutical proteins. Pharm Sci Technol Today, 1, 352-356. (Pubitemid 28526964)
3. Boissel JP, Lee WR, Presnell SR, Cohen FE, Bunn HF. (1993). Erythropoietin structure-function relationships. Mutant proteins that test a model of tertiary structure. J Biol Chem, 268, 15983-93. (Pubitemid 23222105)
4. Bradford MM. (1976). A rapid and sensitive for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem, 72, 248-254.
5. Burg J, Engel A, Franze R, et al. (2006). Erythropoietin Conjugates. US Patent, No, 7128913.
6. Celik E, Calik P, Halloran SM, Oliver SG. (2007). Production of recombinant human erythropoietin from Pichia pastoris; and its structural analysis. J Appl Microbiol, 103, 2084-2094. (Pubitemid 350191149)
7. Celik E, Calik P, Oliver SG. (2009). Fed-batch methanol feeding strategy for recombinant protein production by Pichia pastoris in the presence of co-substrate sorbitol. Yeast, 26, 473-484.
8. Daly R, Hearn MTW. (2005). Expression of heterologous proteins in Pichia pastoris: a useful experimental tool in protein engineering and production. J Mol Recognit, 18, 119-138. (Pubitemid 40328574)
9. Dinkelaar RB, Engels EY, Hart AA, Schoemaker LP, Bosch E, Chamuleau RA. (1981). Metabolic studies on erythropoietin (EP): II. The role of liver and kidney in the metabolism of Ep. Exp Hematol, 9, 796-803.
10. Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA. (2003). Darbepoetin alpha has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol, 31, 290-299. (Pubitemid 36407605)
11. Elliott S, Lorenzini T, Chang D, Barzilay J, Delorme E. (1997). Mapping of the active site of recombinant human erythropoietin. Blood, 8(9), 493-502. (Pubitemid 27051684)
12. Elliott S, Pham E, Macdougall IC. (2008). Erythropoietins: a common mechanism of action. Exp Hematol, 36, 1573-1584.
13. Gross AW, Lodish HF. (2006). Cellular trafficking and degradation of erythropoietin and novel erythropoiesis stimulating protein (NESP). J Biol Chem, 281, 2024-2032. (Pubitemid 43845790)
14. Hamidi M, Azadi A, Rafiei P. (2006). Pharmacokinetic consequences of pegylation. Drug Deliv, 13(6), 399-409. (Pubitemid 44470219)
15. Harris JM, Martin NE, Modi M. (2001). Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet, 40, 539-551. (Pubitemid 32738660)
16. Horton RM. (1993). In Vitro Recombination and mutagnesis of DNA: SOIng together tailor-made genes. In: White BA, ed. Methods in Molecular Biology, Vol. 15: PCR Protocols: Current Methods and Applications. Totawa: Humana Press, 251-266.
17. Jevsevar S, Kunstelj M, Porekar VG. (2010). PEGylation of therapeutic proteins. Biotechnol J, 5, 113-128.
18. Kapre V, Shaligram S, Nho K, Bae G. (2007). N-Terminal PEG-Conjugate of Erythropoietin. IPP WO/2007/010552.
19. Kinstler OB, Brems DN, Lauren SL, Paige AG, Hamburger JB, Treuheit MJ. (1996). Characterization and stability of N-terminally PEGylated rhG-CSF. Pharmaceut Res, 13, 996-1002. (Pubitemid 26258997)
20. Kinstler OB, Gabriel NE, Farrar CE, DePrince RB. (1999). N-terminally chemically modified protein compositions and method. US Patent, No, 5985265.
21. Komatsu N, Nakauchi H, Miwa A, Ishihara T, et al. (1991). Establishment and Characterization of a Human Leukemic Cell Line with Megakaryocytic Features: Dependency on Granulocyte-Macrophage Colony-stimulating Factor, Interleukin 3, or Erythropoietin for Growth and Survival. Cancer Res, 51, 341-348.
22. Kurfurst MM. (1992). Detection and molecular-weight determination of polyethylene glycol-modified hirudin by staining after sodium dodecyl-sulfate polyacrylamide-gel electrophoresis. Anal Biochem, 200, 244-248.
23. Kusterle M, Jevsevar S, Porekar VG. (2008). Size of Pegylated Protein Conjugates Studied by Various Methods. Acta Chim Slov, 55, 594-601.
24. Laemmli UK. (1970). Cleavage of structural proteins during assembly of head of bacteriophage-T4. Nature, 227, 680-685.
25. Leist M, Ghezzi P, Grasso G, et al. (2004). Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science, 305, 239-242. (Pubitemid 38886736)
26. Li P, Anumanthan A, Gao XG, Ilangovan K, Suzara VV, et al. (2007). Expression of recombinant proteins in Pichia pastoris. Appl Biochem Biotechnol, 142(2), 105-24. (Pubitemid 47557234)
27. Long DL, Doherty DH, Eisenberg SP, et al. (2006). Design of homogeneous, monopegylated erythropoietin analogs with preserved in vitro bioactivity. Exp Hematol, 34, 697-704. (Pubitemid 43737103)
28. Macdougall IC, Roberts DE, Coles GA, Williams JD. (1991). Clinical pharmacokinetics of Epoetin (recombinant human erythropoietin). Clin Pharmacokinet, 20, 99-113
29. Markham A, Bryson HM. (1995). Epoetin alpha. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in nonrenal applications. Drugs, 49, 232-254.
30. McGoff P, Baziotis AC, Maskiewicz R. (1988). Analysis of polyethylene glycol modified superoxide dismutase by chromatographic, electrophoretic, light scattering, chemical and enzymatic methods. Chem Pharm Bull, 36(8), 3079-3091.
31. Mosmann T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods, 65, 55-63. (Pubitemid 14203433)
32. Narhi LO, Arakawa T, Aoki KH, Elmore R, Rohde MF, Boone T, Strickland TW. (1991). The effect of carbohydrate on the structure and stability of erythropoietin. J Biol Chem, 266, 23022-6. (Pubitemid 21908754)
33. Spivak JL, Hogans BB. (1989). The in vivo metabolism of recombinant human erythropoietin in the rat. Blood, 73, 90-99. (Pubitemid 19040959)
34. Takeuchi M, Takasaki S, Shimada M, Robata A. (1990). Role of sugar chains in the in vitro biological activity of human erythropoietin produced in recombinant Chinese Hamster Ovary Cells. J Biol Chem, 265, 12127-30.
35. Wang Y-J, Hao S-J, Liu Y-D, Hu T, et al. (2010). PEGylation markedly enhances the in vivo potency of recombinant human non-glycosylated erythropoietin: A comparison with glycosylated erythropoietin. J Control Release, 145, 306-313.
36. Wasley LC, Timoney G, Murtha P, et al. (1991).The importance of N-and O-linked oligosaccharides for the biosynthesis and in vitro and in vivo biologic activities of erythropoietin. Blood, 77, 2624-2632.
37. Wei Z, Menon-Rudolph S, Ghosh-Dastidar P. (2000). Methods and kits for making polypeptides having a single covalently bound N-terminal water soluble polymer. US Patent, No, 6077939.
38. Wojchowski DM, Caslake L. (1989). Biotinylated recombinant human erythropoietins: bioactivity and utility as receptor ligand. Blood, 74, 952-958. (Pubitemid 19210009)
39. Yesland KD. (2008). Pharmacodynamically enhanced therapeutics proteins. US Patent, gt;No, 2008/0171696.